Stellate Ganglion Block for Major Depressive Disorder.
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This is a feasibility study, to investigate a new treatment option for major depressive
disorders by performing a Stellate Ganglion Block (SGB). A SGB is an injection of local
anesthetic into the sympathetic nervous system (peripheral nervous system) located in the
lower part of the neck, to relieve pain in the head, neck, upper arm, and upper chest.
Phase:
Phase 4
Details
Lead Sponsor:
Karim Ladha
Collaborators:
St. Michael's Hospital, Toronto Unity Health Toronto